secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001785530-26-000005
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics announces strategic alternatives review; Q4 2025 net loss $8.4M
--------------------------------------------------------------------------------

- Engaged Piper Sandler as exclusive financial advisor to explore strategic alternatives including sale, merger, or asset sale.
- Cash and equivalents of $57.1M as of Dec 31, 2025; expected to fund operations into Q4 2026.
- Q4 2025 net loss $8.4M vs $20.4M in Q4 2024; R&D expenses $6.9M vs $15.7M.
- Full year 2025 net loss $60.8M vs $70.5M; R&D expenses $44.8M vs $56.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000178553026000005/0001785530-26-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000178553026000005/howl-20260327.htm
  HTML page:      https://secwatch.observer/filing/0001785530-26-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer